ReviewAnalytical cellular pathology (Amsterdam)2015
C1q Nephropathy: The Unique Underrecognized Pathological Entity.
Review in Analytical cellular pathology (Amsterdam), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Clinical Practice Guideline: Microhematuria in Children and Young Adults.Deutsches Arzteblatt international · 2024Guideline
- Characteristics of glomerulonephritis with dominant C1q precipitation compared to corresponding glomerulonephritis without C1q staining on immunofluorescent examination.Kidney research and clinical practice · 2025Article
- Prophylactic anticoagulation in patients with nephrotic syndrome in the Cure Glomerulonephropathy (CureGN) cohort.Clinical kidney journal · 2025Article
- Hepatic tuberculosis induced by rituximab treatment for C1q nephropathy with minimal change disease: a case report.Frontiers in medicine · 2025Article
- Endocapillary proliferative glomerulonephritis associated with Q fever endocarditis: A case report.Clinical case reports · 2024Article
- The appearance of C1q deposition in transplanted kidney allografts and its clinical and histopathologic features.Korean journal of transplantation · 2022Article
- Detection ofFrontiers in genetics · 2022Article
- An Interesting Case of Nonlupus Full-House Nephropathy.Case reports in nephrology · 2021Article
- Host-Specific Serum Factors Control the Development and Survival ofFrontiers in immunology · 2021Article
- Lung Cancer Cell-Derived Secretome Mediates Paraneoplastic Inflammation and Fibrosis in Kidney in Mice.Cancers · 2020Article
- Epidemiology of 10-year paediatric renal biopsies in the region of southern Croatia.BMC nephrology · 2020Article
- Case Report: Complete Remission of C1q Nephropathy Treated With a Single Low-Dose Rituximab, a Reality or Coincidence?Frontiers in pediatrics · 2020Article
- Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder.International journal of molecular sciences · 2019Article
- C1q nephropathy in adults is a form of focal segmental glomerulosclerosis in terms of clinical characteristics.PloS one · 2019Article
- Proliferative lupus nephritis in the absence of overt systemic lupus erythematosus: A historical study of 12 adult patients.Medicine · 2017Observational
- Glomerulonephritis disease pattern at Saudi tertiary care center.Saudi medical journal · 2017Article
- [Advances in clinical research on C1q nephropathy].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Review
- Article
- C1q Nephropathy in Children with Nephrotic Syndrome: Treatment Strategies and Outcomes.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C1q nephropathy is a rare glomerular disease with characteristic mesangial C1q deposition noted on immunofluorescence microscopy. It is histologically defined and poorly understood. Light microscopic features are heterogeneous and comprise minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and proliferative glomerulonephritis. Clinical presentation is also diverse, and ranges from asymptomatic hematuria or proteinuria to frank nephritic or nephrotic syndrome in both children and adults. Hypertension and renal insufficiency at the time of diagnosis are common findings. Optimal treatment is not clear and is usually guided by the underlying light microscopic lesion. Corticosteroids are the mainstay of treatment, with immunosuppressive agents reserved for steroid resistant cases. The presence of nephrotic syndrome and FSGS appear to predict adverse outcomes as opposed to favorable outcomes in those with MCD. Further research is needed to establish C1q nephropathy as a universally recognized distinct clinical entity. In this paper, we discuss the current understanding of pathogenesis, histopathology, clinical features, therapeutic options, and outcomes of C1q nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.